Fodolestan combined with dexamethasone for HAP patients and its effect on serum levels of AngII and FeNO

Abstract

Objective To explore the effect of fodolestan combined with dexamethasone for hospital acquired pneumonia (HAP) patients and its effect on serum levels of angiotensinⅡ (AngⅡ) and fractional exhaled nitric oxide (FeNO). Methods 117 HAP patients who received treatment in Department of Respiratory Medicine in our hospital from November, 2016 to October, 2018 were selected as observation objects. They were randomly divided into an observation group (n=59) and a control group (n=58). The control group were treated with fodolestan, while the observation group with fodolestan and dexamethasone. The clinical efficacy, serum inflammatory factor levels, levels of FeNO and AngⅡ, and the incidence of adverse reactions were compared between the two groups. Results The effective rate was 94.91% in the observation group, and was 81.03% in the control group (P 0.05). Conclusion Fudolestan combined with glucocorticoid is effective in the treatment of HAP, and can inhibit the expressions of AngⅡ and FeNO and reduce inflammatory reaction, so it is worth being generalized. Key words: Fodolestan; Dexamethasone; Hospital acquired pneumonia (HAP)